Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPL-003 in Treatment Resistant Depression
NCT05660642Phase 2Recruiting
- Sponsor
- Beckley Psytech
- Start
- Feb 2023
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of mebufotenin in treatment-resistant depression (TRD) (2 arms), sponsored by Beckley Psytech. Primary endpoint: Safety and Tolerability at 12 weeks. Started Feb 2023; status: recruiting.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05660642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660642.